IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases
Status:
Terminated
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
This study is to assess the efficacy of IMRT combined with erlotinib compared with
whole-brain radiotherapy for EGFR wild type non-small cell lung cancer with 4-10 brain
metastases.